Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study

医学 血管舒缩 更年期 安慰剂 临床试验 随机对照试验 物理疗法 内科学 替代医学 病理
作者
Samuel Lederman,Faith D Ottery,Antonio Cano,Nanette Santoro,Marla Shapiro,Petra Stute,Rebecca C. Thurston,Marci English,Catherine Franklin,Misun Lee,Genevieve Neal-Perry
出处
期刊:The Lancet [Elsevier BV]
卷期号:401 (10382): 1091-1102 被引量:158
标识
DOI:10.1016/s0140-6736(23)00085-5
摘要

Neurokinin 3 receptor antagonists are potential non-hormonal therapies for the treatment of vasomotor symptoms in menopausal women as options are scarce for those who cannot or do not want to take hormone therapy. Fezolinetant is one of the first non-hormonal neurokinin 3 receptor antagonists in development for the treatment of vasomotor symptoms due to menopause. This study investigated the safety and efficacy of fezolinetant for the treatment of moderate-to-severe vasomotor symptoms associated with menopause.SKYLIGHT 1 is a randomised, double-blind, placebo-controlled, 12-week, phase 3 trial with a 40-week active treatment extension. This trial was done at 97 facilities across the USA, Canada, Czech Republic, Hungary, Poland, Spain, and the UK. Women aged 40-65 years with an average of seven or more moderate-to-severe hot flashes per day were randomly assigned (1:1:1) to once-daily exact-matched placebo, fezolinetant 30 mg, or fezolinetant 45 mg. Randomisation was done using a web-based interactive response system and investigators, project team members, clinical staff, and participants were masked to treatment assignment. Coprimary endpoints were mean change in frequency and severity of vasomotor symptoms from baseline to weeks 4 and 12. The efficacy and safety analyses comprised all randomly assigned participants who received at least one dose of study drug. This trial is registered with ClinicalTrials.gov (NCT04003155) and is completed.Between July 11, 2019, and Aug 11, 2021, 2205 women were recruited of whom 175 were assigned to placebo, 176 to fezolinetant 30 mg, and 176 to fezolinetant 45 mg (175 in the placebo group, 174 in the fezolinetant 30 mg group, and 173 in the fezolinetant 45 mg received at least one dose [safety analysis set]). One participant randomly assigned to fezolinetant 45 mg received fezolinetant 30 mg in error, so the efficacy analysis set (full analysis set) consisted of 173 in the fezolinetant 30 mg group and 174 in the fezolinetant 45 mg group. 23 participants in the placebo group, 31 in the fezolinetant 30 mg group, and 13 in the fezolinetant 45 mg group discontinued treatment before week 12, mostly due to adverse events or participant withdrawal. Compared with placebo, fezolinetant 30 mg and fezolinetant 45 mg significantly reduced the frequency of vasomotor symptoms at week 4 (difference in change in least squares mean -1·87 [SE 0·42; p<0·001], -2·07 [SE 0·42; p<0·001]) and week 12 (-2·39 [SE 0·44; p<0·001], -2·55 [SE 0·43; p<0·001]). Compared with placebo, fezolinetant 30 mg and 45 mg significantly reduced the severity of vasomotor symptoms at week 4 (-0·15 [0·06; p=0·012], -0·19 [0·06; p=0·002]) and week 12 (-0·24 [0·08; p=0·002], -0·20 [0·08; p=0·007]). Improvements in frequency and severity of vasomotor symptoms were observed after 1 week and maintained over 52 weeks. During the first 12 weeks, treatment-emergent adverse events occurred in 65 (37%) of 174 women in the fezolinetant 30 mg group, 75 (43%) of 173 in the fezolinetant 45 mg group, and 78 (45%) of 175 in the placebo group. The incidence of liver enzyme elevations was low (placebo n=1; fezolinetant 30 mg n=2; fezolinetant 45 mg n=0) and these events were generally asymptomatic, transient, and resolved while on treatment or after treatment discontinuation.Data support the clinical use of fezolinetant as a non-hormonal treatment for vasomotor symptoms associated with menopause. The study was placebo-controlled for 12 weeks followed by a 40-week blinded extension to assess the maintenance of effect. Furthermore, the population studied was diverse and representative of the potential target population for fezolinetant therapy. Further characterisation of the benefit of fezolinetant on quality of life, including on symptoms of mood and sexual wellbeing, merits investigation.Astellas Pharma.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
余慵慵完成签到 ,获得积分10
1秒前
奋斗的小土豆完成签到,获得积分10
2秒前
ZJJ静完成签到,获得积分10
2秒前
邢大宝完成签到,获得积分10
3秒前
尔玉完成签到 ,获得积分10
5秒前
memo完成签到,获得积分10
5秒前
5秒前
一路芬芳完成签到,获得积分20
5秒前
7秒前
一一一应助songvv采纳,获得10
7秒前
7秒前
SciKid524完成签到 ,获得积分10
9秒前
科研通AI2S应助hhh采纳,获得10
9秒前
QWE完成签到,获得积分10
9秒前
赛赛完成签到 ,获得积分10
11秒前
tinydog完成签到,获得积分10
13秒前
长情琦完成签到,获得积分10
13秒前
Mercury完成签到 ,获得积分10
15秒前
zx完成签到 ,获得积分10
16秒前
Dearjw1655完成签到,获得积分10
17秒前
123完成签到 ,获得积分10
17秒前
圆圆完成签到 ,获得积分10
18秒前
22秒前
哭泣笑柳发布了新的文献求助10
23秒前
张宁波完成签到,获得积分10
23秒前
OeO完成签到 ,获得积分10
23秒前
macboy完成签到,获得积分10
25秒前
biubiu完成签到,获得积分10
26秒前
咸鱼之王完成签到,获得积分10
27秒前
比比谁的速度快给ljm的求助进行了留言
27秒前
Can完成签到,获得积分10
28秒前
hhh完成签到,获得积分10
28秒前
qqq发布了新的文献求助10
28秒前
E0702完成签到,获得积分10
28秒前
30秒前
lin完成签到 ,获得积分20
31秒前
乐乐应助科研通管家采纳,获得10
34秒前
34秒前
34秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038184
求助须知:如何正确求助?哪些是违规求助? 3575908
关于积分的说明 11373872
捐赠科研通 3305715
什么是DOI,文献DOI怎么找? 1819255
邀请新用户注册赠送积分活动 892662
科研通“疑难数据库(出版商)”最低求助积分说明 815022